Inhibition of NOS using 2-aminoguanidine, i-NOS and L-N[6-(1-iminoethyl) lysine 5-tetrazole amide has been shown to be neuroprotective in experimental glaucoma models.[93] Nipradilol, a β- and α1 antagonist has also been shown to be neuroprotective.[94, 95] However, Pang et al., in a recent study, found no proof for the release of NOS-2 by astrocytes in patients or models. The gene discussed is NOS1; the disease is glaucoma.